National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

STATUTORY RULES

1968 No.

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1968.*

I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1968.

Dated this twenty-ninth day of November, 1968.

CASEY

Governor-General.

By His Excellency's Command,

(SGD.) A, J. FORBES

Minister of State for Health.

Amendments of the National Health (Pharmaceutical Benefits)  regulations 

Commencement.

1. These Regulations shall come into operation on the first day of December, 1968.

First Schedule.

2. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting item 57 and inserting in its stead the following item:—

" 57. Chloroquine Phosphate ".

Second Schedule.

3. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the First Schedule to these Regulations.

Third Schedule.

4. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Second Schedule to these Regulations.

Fifth Schedule.

5. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is repealed and the following Schedule inserted in its stead:—

* Notified in the Commonwealth Gazette on  1968.

  Statutory Rules I960, No. 17, as amended to date. For previous amendments of the National Health (Pharmaceutical Benefits) Regulations, see footnote to Statutory Rules 1968, No. 44, and see also Statutory Rules 1968, Nos. 44, 76 and 88.

24573/68—Price 30c  15/20.11.1968

FIFTH SCHEDULE

Regulation 14.

Pharmaceutical Benefits the Prescribing of Which is Subject to Conditions and Restrictions

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
1	Acetylcysteine...................................................	Fibrocystic disease
2	(1) Acetylsalicylic Acid Tablets, B.P	Any disease or condition in a pensioner
(2) Soluble Acetylsalicylic Acid Tablets B.P.
(3) Acetylsalicylic Acid with Paracetamol and Caffeine Tablets
(4) Acetylsalicylic Acid with Codeine Phosphate and Pentobarbitone Sodium
3	Acrylic Resin ...................................................	Ileostomy or colostomy conditions
4	Aldosterone ...................................................	With the written authority of the Director-General, treatment of an acute crisis in—
Addison's disease
Salt-losing congenital adrenal hypoplasia
5	Allopurinol ...................................................	Chronic gout not responding to other pharmaceutical benefits
Gout associated with renal failure
6	Aloxiprin ...................................................	Any disease or condition in a pensioner
7	Aluminium Hydroxide Gel with Kaolin................................................	Ileostomy or colostomy conditions
8	Aluminium Acetylsalicylate Tablet	Any disease or condition in a pensioner
9	Aminocaproic Acid...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
10	(1) Amitriptyline Hydrochloride ...................................................	Any disease or condition in a pensioner
(2) Amitriptyline Tablets, B.P	Any disease or condition in a patient receiving treatment in or at an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Amitriptyline Hydrochloride or Amitriptyline Tablets, B.P.
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
11	Amphetamine Sulphate Tablets, B.P.	Any disease or condition in a pensioner
12	Amphotericin B ...................................................	Systemic fungal infection
13	(1) Ampicillin Capsules, B.P...................................................	With the written authority of the Director-General—
(2) Ampicillin Injections, Tablets	Gram-negative infections in pregnant women
and Suspension	Infections in children, in which penicillin and sulphonamides are not effective
Infections where positive bacteriological evidence confirms that ampicillin is an appropriate therapeutic agent and the Director-General is satisfied that it is the most appropriate therapeutic agent in all the circumstances of the case
Acute infections threatening the life of a patient where clinical evidence shows that ampicillin is an appropriate therapeutic agent and the Director-General is satisfied that it is the most appropriate therapeutic agent in all the circumstances of the case
Chronic bronchitis complicated by emphysema where other therapeutic agents have failed

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be proscribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
14	Aneurine Hydrochloride Tablets B.P.	Any disease or condition in a pensioner
15	Angiotensin Amide ...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
16	Ascorbic Acid Tablets, B.P...................................................	Any disease or condition in a pensioner
17	(1) Azathioprine ...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Beclamide
18	Benzoin Compound Tincture, B.P.C.	Ileostomy or colostomy conditions
19	Benzylpenicillin Injection, 5,000,000 units	Bacterial endocarditis or septicaemia
20	Benzylpenicillin Injection, 10,000,000 units	Bacterial endocarditis or septicaemia Gastrointestinal surgery
21	(1) Benzylpenicillin with Streptomycin Sulphate	Endocarditis due to Streptococcus faecalis or Streptococcus viridans
(2) Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate
22	Betamethasone Tablets ..............	With the written authority of the Director-General—
Acquired haemolytic anaemia
Acute disseminated encephalomyelitis
Acute exfoliative dermatitis
Acute exophthalmic ophthalmoplegia
Acute heart block complicating myocardial infarction
Acute phase of herpes zoster
Acute rheumatic carditis
Adrenogenital syndrome
Agranulocytosis
Behcet's syndrome
Benign intracranial hypertension
Cerebral oedema
Cerebral tumors
Cranial arteritis
Cushing's syndrome including hyperadrenocorticalism
Dermatomyositis
Encephalitis
Encephalomyelitis
Giant cell thyroiditis proven by biopsy
Guillain-Barre syndrome
Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
Hansen's disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin's disease
Hypoplastic anaemia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Interstitial keratitis dueto syphilis or vernal conjunctivitis
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Malignancy treatment in conjunction with radiotherapy or chemotherapy
Meningitis
Metastatic breast cancer
Mycosis fungoides

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
22	Betamethasone Tablets—continued	Nephrosis or nephrotic syndrome
Neuromyelitis optica
Nodular non-suppurative panniculitis (Christian-Weber disease)
Oedema of the spinal cord following trauma or infections
Optic neuritis following removal of tumors of the brain
Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis
Pseudohermaphroditism
Pulmonary eosinophilia
Purpura, Henoch's
Regional ileitis (Crohn's disease)
Reticulum cell sarcoma
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Sneddon and Wilkinson's subcorneal pustular dermatosis
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation for those patients under steroid therapy
Stevens-Johnson syndrome
Still's disease in children under the age of sixteen years
Systemic lupus erythematosus
Sympathetic ophthalmitis
Temporal arteritis
Thrombocytopenic purpura
Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
Type II nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report.
23	Betamethasone Acetate and Betamethasone Alcohol Injection	Intra-articular use
24	Betamethasone Sodium Phosphate Injection, B.P.	Intra-articular use
25	Buclosamide and Salicylic Acid	For the treatment of diseases of the car
26	Buclosamide, Salicylic Acid and Hydrocortisone Acetate	For the treatment of diseases of the car
27	Busulphan Tablets, B.P...................................................	Treatment in neoplastic disease
28	(1) Calciferol Tablets, B.P..................................................	Any disease or condition in a pensioner
(2) Calciferol, B.P..................................................	With the written authority of the Director-General—
Hypoparathyroidism
Chronic hypoparathyroid tetany
Vitamin D-resistant rickets
29	Calcium Aminosalicylate..................................................	Tuberculosis
30	Carbamazepine..................................................	Epilepsy
Trigeminal neuralgia
31	(1) Carbenoxolone Sodium..................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Cephaloridine..................................................
32	Charcoal Tablets..................................................	Ileostomy or colostomy conditions
33	Chlorambucil Tablets, B.P..................................................	Treatment in neoplastic disease
34	Chloramine Deodorant Tablets and Powder	Ileostomy or colostomy conditions

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
35	Chloramphenicol Capsules, B.P.	Bacterial meningitis
Haemophilus influenzae infections
Intra-ocular infections
Rickettsial infections
Salmonella septicaemia
Typhoid and paratyphoid
Other serious infections sensitive only to Chloramphenicol Capsules, B.P.
36	(1) Chloramphenicol Injections........................................................	A disease or condition specified in this column in relation to Chloramphenicol Capsules, B.P.
(2) Chloramphenicol Tablets ........................................................
(3) Chloramphenicol Oral Suspension
37	Chlorotrianisene Tablets........................................................	Carcinoma of the prostate
38	(1) Chlorpromazine Hydrochloride, B.P.	Any disease or condition in a pensioner
Any disease or condition in a patient receiving treatment in or at tin approved hospital
(2) Chlorpromazine Injection, B.P.
(3) Chlorpromazine Tablets, B.P.	The treatment of a mental disorder in a person who hits, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, B.P., Chlorpromazine Hydrochloride Injection, B.P., or Chlorpromazine Tablets, B.P.
With the written authority of the Director-General—
Late-stage malignancy
Radiation sickness
Huntington's chorea
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
39	Chlortetracycline Capsules, B.P....	Brucellosis
Herpes zoster opthalmicus
Intestinal amoebiasis
Leptospirosis
Lymphogranuloma venereum
Psittacosis
Rickettsial infections
Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
40	Chlortetracycline Hydrochloride Granules	A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P.
41	(1) Cloxacillin Sodium, B.P........................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Cloxacillin Capsules, B.P
42	(1) Codiene Phosphate with Acetylsalicylic Acid Soluble Tablets	Any disease or condition in a pensioner
(2) Codiene Phosphate with Acetylsalicylic Acid Tablets
(3) Codeine Phosphate with Acetylsalicylic Acid and Paracetamol Soluble Tablets
(4) Codeine Phosphate with Acetylsalicylic Acid, Paracetamol and Caffeine Tablets
43	Cod Liver Oil Emulsion ........................................................	Any disease or condition in a child under the age of twelve years or in a pensioner

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
44	Colistin Sulphomethate Injection, B.P.	Pyocyaneus infection and Gram-negative infections where no other drug is effective
45	(1) Corticotrophin Injection, B.P.	With the written authority of the Director-General—
(2) Corticotrophin Gelatin Injection, B.P.	The prevention of side effects of corticosteroid therapy
(3) Corticotrophin Zinc Hydroxide Injection, B.P.	Acquired haemolytic anaemia
Acute disseminated encephalomyelitis
Acute exacerbations of multiple sclerosis
Acute exfoliative dermatitis
Acute phase of Bell's Palsy
Acute rheumatic carditis
Addison's disease or other forms of adrenocortical hypoplasia
Adrenogenital syndrome
Agranulocytosis
Behcet's syndrome
Cranial arteritis
Cushing's syndrome including hyperadrenocorticalism
Dermatomyositis
Encephalomyelitis
Giant cell thyroiditis proven by biopsy
Guillain-Barré syndrome
Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
Hansen's disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin's disease
Hypoplastic anaemia
Hypsarrhythmia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Metastatic breast cancer
Mycosis fungoides
Nephrosis or nephrotic syndrome
Neuromyelitis optica
Optic neuritis following removal of tumors of the brain
Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis
Pseudohermaphroditism
Pulmonary cosinophilia
Purpura, Henoch's
Regional ileitis (Crohn's disease)
Reticulum cell sarcoma
Salaam convulsions
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation for those patients under steroid therapy
Stevens-Johnson syndrome

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
45	(1) Corticotrophin Injection, B.P.	Still's disease in children under the age of sixteen years
(2) Corticotrophin Gelatin Injection, B.P.
Systemic lupus erythematosus
(3) Corticotrophin Zinc Hydroxide	Sympathetic ophthalmitis
Injection, B.P.—continued	Temporal arteritis
Thrombocytopenic purpura
Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
Type II nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
46	Cortisone Injection, B.P.........................................................	With the written authority of the Director-General—
Acute exophthalmic ophthalmoplegia
Acute heart block complicating myocardial infarction
Anaemia, acquired haemolytic
Addison's disease
Adrenocortical hypoplasia
Adrenalectomy, total
Adrenogenital syndrome
Agranulocytosis
Behcet's syndrome
Benign intracranial hypertension
Cerebral tumours and cerebral oedema
Cranial arteritis
Cushing's syndrome, including hyperadrenocorticalism
Dermatitis, acute exfoliative
Dermatomyositis
Encephalitis
Encephalomyelitis
Encephalomyelitis, acute disseminated

Giant cell thyroiditis proven by biopsy

Guillain-Barré syndrome

Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis

Hansen's disease

Hepatitis, progressive or continuing, proven by biopsy or biochemistry

Hodgkin's disease

Hypoplastic anaemia

Idiopathic hypercalcaemia

Inflammatory conditions of the uveal tract and retina

Interstitial keratitis due to syphilis or vernal conjunctivitis

Keratoplasty

Leucine sensitive hypoglycaemia

Leukaemia

Lymphosarcoma and follicular lymphoma

Meningitis

Metastatic breast cancer

Mycosis fungoides

Nephrosis or nephrotic syndrome

Neuromyelitis optica

Oedema of the spinal cord following trauma or infection

Optic neuritis following removal of tumor of the brain

Panhypopituitarism

Pemphigus

Periarteritis

Progressive transverse myelitis

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
46	Cortisone Injection, B.P.—continued	Pseudohermaphroditism
Pulmonary cosinophilia
Purpura, Henoch's
Purpura, thrombocytopenic
Regional ileitis (Crohn's disease)
Reticulum cell sarcoma
Rheumatic carditis, acute
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation in patients under steroid therapy
Stevens-Johnson syndrome
Still's disease in a child under the age of sixteen years
Sneddon and Wilkinson's sub-corneal pustular dermatosis
Sympathetic ophthalmitis
Systemic lupus erythematosus
Temporal arteritis
Treatment of malignancy in conjunction with radiotherapy or chemotherapy
Tropical and non-tropical sprue and all forms of malabsorption associated with those diseases
Type II Nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
47	Cortisone Tablets, B.P..........................................................	With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection, B.P.
48	Cyanocobalamin Injection, B.P..........................................................	Established megalocytic anaemia
Neuroblastoma
Sub-acute combined degeneration of the cord
Treatment in post-gastrectomy
49	Cymogran	With the written authority of the Director-General, phenylketonuria
50	(1) Cycloserine Tablets, B.P..........................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Cycloserine Capsules, B.P.
51	(1) Demethylchlortetracycline Capsules, B.P.	A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P., except herpes zoster ophthalmicus
(2) Demethylchlortetracycline
Hydrochloride Oral Paediatric
Drops and Oral Suspension
52	Demethylchlortetracycline Hydrochloride with Nystatin	Any disease or condition specified in this column in relation to Oxytetracycline Hydrochloride with a buffering agent and Nystatin
53	Deodorant Detergent Solution (Terric with Spearmint Oil and Cetrimide)	Ileostomy or colostomy conditions
54	(1) Deoxycortone Aqueous Injections	Addison's disease
Adrenalectomy, total
(2) Deoxycortone Acetate Injection, B.P.
(3) Deoxycortone Trimethylacetate Injection, B.P.
(4) Deoxycortone Acetate Implants, B.P.
(5) Deoxycortone Acetate Tablets
55	Desferrioxamine ..........................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
56	Dexamethasone Tablets, B.P........................................................	With the written authority of the Director-General—
Acquired haeomolytic anaemia
Acute disseminated encephalomyelitis
Acute exfoliative dermatitis
Acute exophthalmic ophthalmoplegia
Acute heart block complicating myocardial infarction
Acute phase of herpes zoster
Acute rheumatic carditis
Adrenogenital syndrome
Agranulocytosis
Behcet's syndrome
Benign intracranial hypertension
Cerebral oedema
Cerebral tumors
Cranial arteritis
Cushing's syndrome including hyperadrenocorticalism
Dermatomyositis
Encephalitis
Encephalomyelitis
Giant cell thyroiditis proven by biopsy
Guillain-Barré syndrome
Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
Hansen's disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin's disease
Hypoplastic anaemia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Interstitial keratitis due to syphilis or vernal conjunctivitis
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Malignancy treatment in conjunction with radiotherapy or chemotherapy
Meningitis
Metastatic breast cancer
Mycosis fungoides
Nephrosis or nephrotic syndrome
Neuromyelitis optica
Nodular nonsuppurative panniculitis (Christian-Weber disease)
Oedema of the spinal cord following trauma or infections
Optic neuritis following removal of tumors of the brain
Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis
Pseudohermaphroditism
Pulmonary eosinophilia
Purpura, Henoch's
Regional ileitis (Crohn's disease)
Reticulum cell sarcoma
Sarcoidosis
Scleroderma

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
56	Dexamethasone Tablets, B.P.—continued	Severe reactions of the skin and mucosa following X-ray therapy
Sneddon and Wilkinson's subcorneal pustular dermatosis
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation for those patients under steroid therapy
Stevens-Johnson syndrome
Still's disease in children under the age of sixteen years
Systemic lupus erythematosus
Sympathetic ophthalmitis
Temporal arteritis
Thrombocytopenic purpura
Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
Type II nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
57	Dexamethasone Sodium Phosphate	Intra-articular use
Injections	Cerebral oedema
58	Dexamphetamine Tablets, B.P.............	Any disease or condition in a pensioner
59	(1) Dextromoramide Tablets................	Treatment in neoplastic disease
(2) Dextromoramide Injection
60	Diazepam Injection ............................	Cardioversion
Endoscopic examination
Epilepsy
Minor operative procedure
Premedication induction of anaesthesia
Upper motor neurone lesion
61	Diazepam Syrup and 10 mg. tablet	Epilepsy
Upper motor neurone lesion
62	Diazepam Tablets 2 mg. and 5 mg.	Epilepsy
Upper motor neurone lesion
Treatment in multiple sclerosis
Stiff-man syndrome
63	Dienoestrol Cream .............................	Any disease or condition in a pensioner
64	Dienoestrol Tablets, B.P......................	Carcinoma of the prostate
Mammary carcinoma
Any disease or condition in a pensioner
65	Dihydrotachysterol.............................	Parathyroid deficiency
66	Diloxanide Furoate Tablets, B.P..........	Amoebic dysentery
67	Dimethicone	Ileostomy or colostomy conditions
68	Dimethicone Creams...........................	Use with surgical appliances
69	Dioctyl Sodium Sulphosuccinate with Danthron	Any disease or condition in a pensioner
70	Disodium Stilboestrol Diphosphate	Carcinoma of the prostate
71	Ditophal	Any disease or condition in a patient receiving treatment in or at an approved hospital
72	Doxycycline Hyclate ..........................	A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P. except herpes zoster ophthalmicus
73	(1) Erythromycin................................	Brucellosis
Intestinal amoebiasis
(2) Erythromycin ethyl succinate suspension	Leptospirosis
Lymphogranuloma venereum
(3) Erythromycin ethyl succinate	Mycoplasma pneumoniae (Eaton's Agent)
chewable tablet	Psittacosis
Rickettsial infections
Staphylococcal septicaemia or staphylococcal pneumonia

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
73	(1) Erythromycin.........................................................	Any bacterial infections or spirochaetal infection or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
	(2) Erythromycin ethyl succinate suspension .........................................................
(3) Erythromycin ethyl succinate chewable tablet—continued
	Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
74	Ethinyloestradiol Tablets, B.P.........................................................	Any disease or condition in a pensioner
Hereditary telangiectasis
Pre-menopausal castration syndrome
Turner's syndrome
75	Ethionamide	Tuberculosis
76	Ethisterone Tablets, B.P.........................................................	Turner's syndrome
77	Ethyloestrenol .........................................................	With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long term treatment with corticosteroids
78	Fludrocortisone Tablets, B.P.........................................................	Addison's disease
Adrenocortical hypoplasia
Total adrenalectomy
79	Flufenamic Acid.........................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
80	Fluorouracil Sodium .........................................................	Treatment in neoplastic disease
81	Fluoxymesterone Tablets, B.P.........................................................	Castration syndrome (male)
Mammary carcinoma
With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
82	(1) Fluphenazine Oenanthate .........................................................	Any disease or condition in a pensioner
(2) Fluphenazine Hydrochloride.........................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits:—
Fluphenazine Oenanthate
Fluphenazine Hydrochloride
With the written authority of the Director-General—
Late-stage malignancy
Radiation sickness
Huntington's chorea
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
83	(1) Folic Acid Injection .........................................................	Macrocytic anaemia
(2) Folic Acid Tablets, B.P.........................................................	Sprue or the sprue-like syndrome
84	Folinic Acid .........................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
85	Framycetin Sulphate Tablets .........................................................	Bowel sterilization preparatory to major surgery
86	Fusidic Acid (Sodium Salt or Diethanolamine Salt)	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Fusidic Acid (Sodium Salt or Diethanolamine Salt) is the only appropriate antibiotic

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
87	Galactomin Formula No. 11..................................................	With the written authority of the Director-General—
Galactosaemia
Conditions needing an extreme restriction of lactose in the patient's diet, in children under the age of four years
88	Galactomin Formula No. 19 ..................................................	With the written authority of the Director-General— Glucose-galactose malabsorption
89	Goat's Milk, dehydrated..................................................	With the written authority of the Director-General, cow's milk allergy in children under the age of four years
90	Goat's Milk, Whole (Sterilized) ..................................................	With the written authority of the Director-General— Cow's milk allergy in children under the age of four years
91	Griseofulvin Tablets, B.P..................................................	With the written authority of the Director-General, for use in severe tinea infections due to Microsporum, Trichophyton or Epidermophyton species which have been proven by laboratory examination
92	Guanacline Tablets..................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
93	Halibut Liver Oil Capsules..................................................	Any disease or condition in a pensioner
94	Haloperidol ..................................................	Any disease or condition in a pensioner
Any disease or condition in a patient receiving treatment in or at an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that the person received treatment at that hospital and may require further treatment with Haloperidol
With the written authority of the Director-General—
Late-stage malignancy
Radiation sickness
Huntington's chorea
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
93	(1) Hexachlorophane with Chloroxylenol	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Hexachlorophane with Entsufon
(3) Hexachlorophane with Lissapol
(4) Hexachlorophane in Soap Solution
96	Hydrocortisone Injection ..................................................	With the written authority of the Director-General—
Acquired haemolytic anaemia
Acute disseminated encephalomyelitis
Acute exfoliative dermatitis
Acute exophthalmic ophthalmoplegia
Acute heart block complicating myocardial infarction
Acute rheumatic carditis
Addison's disease or other forms of adrenocortical hypoplasia
Adrenalectomy, total
Adrenogenital syndrome
Agranulocytosis
Behcet's syndrome
Benign intracranial hypertension
Cerebral oedema

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
96	Hydrocortisone Injection—continued	Cerebral tumors
Cranial arteritis
Cushing's syndrome including hyperadrenocorticalism
Dermatomyositis
Encephalitis
Encephalomyelitis
Giant cell thyroiditis proven by biopsy
Guillain-Barré syndrome
Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
Hansen's disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin's disease
Hypoplastic anaemia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Interstitial keratitis due to syphilis or vernal conjunctivitis
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Malignancy treatment in conjunction with radiotherapy or chemotherapy
Meningitis
Metastatic breast cancer
Mycosis fungoides
Nephrosis or nephrotic syndrome
Neuromyelitis optica
Oedema of the spinal cord following trauma or infections
Optic neuritis following removal of tumors of the brain
Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis

Pseudohermaphroditism

Pulmonary cosinophilia

Purpura, Henoch's

Regional ileitis (Crohn's disease)

Reticulum cell sarcoma

Sarcoidosis

Scleroderma

Severe reactions of the skin and mucosa following X-ray therapy

Sneddon and Wilkinson's subcorneal pustular dermatosis

Splenic neutropenia

Status asthmaticus

Steroid therapy prior to operation for those patients under steroid therapy

Stevens-Johnson syndrome

Still's disease in children under the age of sixteen years

Systemic lupus erythematosus

Sympathetic ophthalmitis

Temporal arteritis

Thrombocytopenic purpura

Tropical and non-tropical sprue and forms of malabsorption associated with these diseases

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
96	Hydrocortisone Injection—continued	Type II nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
97	Hydrocortisone Acetate Injection, B.P.	Intra-articular use
98	Hydrocortisone Acetate, B.P. with Neomycin Sulphate, B.P. Ear drops and ear ointment	For the treatment of diseases of the ear
99	Hydrocortisone Sodium Succinate Injection	Acute adrenal failure due to medical or surgical crisis Prophylaxis of adrenal insufficiency during and after major surgery for patients already on steroid therapy
Stevens-Johnson syndrome
100	Hydrocortisone Ear Drops ...........	For the treatment of diseases of the ear
101	Hydroxocobalmin Injection, B.P...	Established megalocytic anaemia
Neuroblastoma
Sub-acute combined degeneration of the cord
Treatment in post-gastrectomy
102	Hydroxyprogesterone ..................	Endometrial carcinoma
Progresterone deficiency proven by hormonal assay of lateral wall smear
103	Idoxuridine .................................	Infections caused by Herpes Simplex Virus
104	(1) Imipramine Tablets, B.P..........	Any disease or condition in a pensioner
(2) Imipramine Hydrochloride, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Imipramine Hydrochloride B.P. or Imipramine Tablets, B.P.
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
105	Indomethacin Capsule .................	Rheumatoid arthritis or osteoarthritis not responding to salicylates
Acute attacks of gout
Ankylosing spondylitis
Psoriatic arthritis
Reiter's syndrome
106	Indomethacin Suppositories .........	For the treatment of the following conditions in persons who cannot tolerate oral indomethacin—
Acute attacks of gout
Ankylosing spondylitis
Osteoarthritis not responding to salicylates
Psoriatic arthritis
Reiter's syndrome
Rheumatoid arthritis not responding to salicylates
107	Isoniazid Tablets, B.P...................	Tuberculosis
108	Isoprenaline Hydrochloride Tablets	For long term use in patients suffering from Stokes-Adams' seizures due to heart block
109	Kanamycin Sulphate Capsules, Injections and Oral Solution	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the only appropriate antibiotic
110	Kitasamycin ................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
111	Levorphanol Tartrate....................	Obstetrical use Severe intractable pain

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whoso treatment it may be prescribed) for supply under Part VII. of the Act
112	Lincomycin Hydrochloride .................................................	Gram positive coccal infections
Osteomyelitis
113	Liothyronine Tablets, D.P.................................................	Myxoedema
114	Lipopancreatin.................................................	Fibrocystic disease
Pancreatico-duodenectomy
Pancreatic steatorrhea
115	Lofenalac .................................................	With the written authority of the Director-General, phenylketonuria
116	Medroxyprogesterone Acetate Tablets 2.5 mg. and 10 mg.	Adenocarcinoma of the uterus (endometrial carcinoma)
117	Medroxyprogesterone Acetate Tablets 100 mg.	Adenocarcinoma of the body of the uterus Hypernephroma
118	Medroxyprogesterone Acetate Injections	Adenocarcinoma of the uterus (endometrial carcinoma) Hypernephroma
Progesterone deficiency proven by hormonal assay of lateral wall smear
119	Melphalan .................................................	Treatment in neoplastic disease
120	Mercaptopurine Tablets, B.P.................................................	Allergic angiitis
Treatment in neoplastic disease
Lupus erythematosus
Nephrosis or Nephrotic syndrome
Periarteritis
121	Mestanolone .................................................	Mammary carcinoma
With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
123	Methacycline .................................................	A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P., except herpes zoster ophthalmicus
123	(1) Methandienone Tablets, B.P..................................................	With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
(2) Methenolone Acetate.................................................
Intermittent use for patients on long-term treatment with corticosteroids
124	Methicillin Injection, B.P.................................................	Proven or suspected staphylococcal septicaemia
125	Methotrexate Tablets.................................................	Treatment in neoplastic disease
126	Methotrexate Injections.................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
127	(1) Methylamphetamine Injection, B.P.	Any disease or condition in a pensioner
(2) Methylamphetamine Tablets, B.P.
128	(1) Methylprednisolone Tablets, B.P.	With the written authority of the Director-General—
Acquired haemolytic anaemia
(2) Methylprednisolone Capsules	Acute disseminated encephalomyelitis
Acute exfoliative dermatitis
Acute exophthalmic ophthalmoplegia
Acute heart block complicating myocardial infarction
Acute phase of herpes zoster
Acute rheumatic carditis
Adrenogenital syndrome
Agranulocytosis
Behcet's syndrome
Benign intracranial hypertension
Cerebral oedema
Cerebral tumors
Cranial arteritis
Cushing's syndrome including hyperadrenocorticalism
Dermatomyositis

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
128	(1) Methylprednisolone Tablets, B.P.	Encephalitis
Encephalomyelitis
(2) Methylprednisolone Capsules—continued	Giant cell thyroiditis proven by biopsy
Guillain-Barré syndrome
Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
Hansen's disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin's disease
Hypoplastic anaemia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Interstitial keratitis due to syphilis or vernal conjunctivitis
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Malignancy treatment in conjunction with radiotherapy or chemotherapy
Malignant exophthalmos
Meningitis
Metastatic breast cancer
Mycosis fungoides
Nephrosis or nephrotic syndrome
Neuromyelitis optica
Nodular nonsuppurative panniculitis (Christian-Weber disease)
Oedema of the spinal cord following trauma or infections
Optic neuritis following removal of tumors of the brain
Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis
Pseudohermaphroditism
Pulmonary cosinophilia
Purpura, Henoch's
Regional ileitis (Crohn's disease)
Reticulum cell sarcoma
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Sneddon and Wilkinson's subcorneal pustular dermatosis
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation for these patients under steroid therapy
Stevens-Johnson syndrome
Still's disease in children under the age of sixteen years
Systemic lupus erythematosus
Sympathetic ophthalmitis
Temporal arteritis
Thrombocytopenic purpura
Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
Type II nephritis
Ulcerative colitis proved by sigmoidoscopy or radiological report

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
129	(1) Methyltestosterone Tablets, B.P.	Castration syndrome (male)
Klinefelter Reifenstein Albright syndrome
(2) Methyltestosterone, B.P. ..	Mammary carcinoma
130	Metyrapone ................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
131	Minafen ......................................	With the written authority of the Director-General, phenylketonuria
132	Morphine Sulphate, B.P. with Tacrine Tablets	Severe intractable pain
133	Mustine Hydrochloride Injection	Treatment in neoplastic disease
134	Nalidixic Acid.............................	Urinary tract infections in which sulphonamides are not effective
135	Nandrolone Phenylpropionate Injection, B.P.	Mammary carcinoma
With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
136	Nandrolone Decanoate ................	Mammary carcinoma
With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
137	Natamycin	Monilia infections
138	Neomycin Sulphate Powder .........	With the written authority of the Director-General, intermittent use by inhalation in fibrocystic disease
139	Neomycin Sulphate, B.P. with Gramicidin, Thonzonium Bromide, Thonzylamine Hydrochloride and Hydrocortisone Acetate, B.P.	For the treatment of diseases of the car
140	Neomycin Tablets, B.P.................................................... .	Bowel sterilization preparatory to major surgery
Portal-systemic encephalopathy
141	Neomycin Undecenoate with Bacitracin Zinc	For the treatment of diseases of the ear
142	Nicotinic Acid Tablets, B.P..........	Any disease or condition in a pensioner
143	Nitrazepam	Myoclonic epilepsy in children
144	(1) Nitrofurantoin Tablets, B.P......	Urinary tract infections
(2) Nitrofurantoin Oral Suspension
145	Nitromin .....................................	Treatment in neoplastic disease
146	(1) Nortriptyline Hydrochloride, B.P.	Any disease or condition in a pensioner
Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Nortriptyline Tablets, B.P........
(3) Nortriptyline Capsules, B.P.....	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Nortriptyline Hydrochloride, B.P., Nortriptyline Tablets, B.P. or Nortriptyline Capsules, B.P.
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
147	Nutramigen .................................	With the written authority of the Director-General—
Cow's milk allergy in children under the age of four years
Galactosaemia
Lactose intolerance
Fibrocystic disease of the pancreas

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
148	Nystatin Tablets, B.P....................	Monilia infections
149	Orciprenaline Sulphate Injection...	Any disease or condition in a patient receiving treatment in or at an approved hospital
150	Oxycodone Pectinate....................	Treatment in neoplastic disease
151	Oxymesterone.............................	With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
152	Oxymetholone ............................	With the written authority of the Director-General—
Aplastic anaemia
Primary refractory anaemias
153	(1) Oxytetracycline Hydrochloride Capsules	A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P., except herpes zoster ophthalmicus
(2) Oxytetracycline Tablets, B.P...
(3) Oxytetracycline Injections.......
(4) Calcium di-Oxytetracycline Oral Suspension
(5) Calcium di-Oxytetracycline Paediatric Drops
154	Oxytetracycline Hydrochloride with a buffering agent and Nystatin	Broad spectrum antibiotic therapy of premature infants, of patients under steroid therapy or of cases complicated by intestinal moniliasis
A second or repeated course of broad spectrum antibiotic therapy for a disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P., except herpes zoster ophthalmicus
155	(1) Pancreatin, B.P.......................	Fibrocystic disease
(2) Pancreatin Enzyme U.S.N.F. XII	Pancreatico-duodenectomy
Pancreatic steatorrhea
156	Para-Aminosalicyclic Acid...........	Tuberculosis
157	(1) Paracetamol Suspension..........	Any disease or condition in a pensioner
(2) Paracetamol Tablets, B.P.
158	Paracetamol with Codeine Phosphate and Pentobartitone Sodium	Any disease or condition in a pensioner
159	Paramethasone Acetate ................	With the written authority of the Director-General—
Acquired haemolytic anaemia
Acute disseminated encephalomyelitis
Acute exfoliative dermatitis
Acute exophthalmic ophthalmoplegia
Acute heart block complicating myocardial infarction
Acute phase of herpes zoster
Acute rheumatic carditis
Addison's disease or other forms of adrenocortical  hypoplasia
Adrenalectomy, total
Adrenogenital syndrome
Agranulocytosis
Behcet's syndrome
Benign intracranial hypertension
Cerebral oedema
Cerebral tumors
Cranial arteritis
Cushing's syndrome including hyperadrenocorticalism
Dermatomyositis
Encephalitis
Encephalomyelitis
Giant cell thyroiditis proven by biopsy
Guillain-Barré syndrome
Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
159	Paramethasone Acetate—continued	Hansen's disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin's disease
Hypoplastic anaemia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Interstitial keratitis due to syphilis or vernal conjunctivitis
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Malignancy treatment in conjunction with radiotherapy or chemotherapy
Meningitis
Metastatic breast cancer
Mycosis fungoides
Nephrosis or nephrotic syndrome
Neuromyelitis optica
Oedema of the spinal cord following trauma or infections
Optic neuritis following removal of tumors of the brain
Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis
Pseudohermaphroditism
Pulmonary eosinophilia
Purpura, Henoch's
Regional ileitis (Crohn's disease)
Reticulum cell sarcoma
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Sneddon and Wilkinson's subcorneal pustular dermatosis
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation for those patients under steroid therapy
Stevens-Johnson syndrome
Still's disease in children under the age of sixteen years
Systemic lupus erythematosus

Sympathetic ophthalmitis
Temporal arteritis
Thrombocytopenic purpura
Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
Type II nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
160	(1) Paraffin Liquid Emulsion..................................................	Any disease or condition in a pensioner
(2) Paraffin Liquid Emulsion with Phenolphthalein
161	Pargyline Hydrochloride..................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions us to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
162	Penicillamine..................................................	With the written authority of the Director-General—
Cystinosis
Cystinuria with calculus formation
Treatment of cold agglutinin haemoglobinuria
Acute heavy metal intoxication
Wilson's disease (hepatolenticular degeneration)
163	(1) Penicillin Benzathine Tablets and Capsules	Prevention of recurrent streptococcal infections, including rheumatic fever
(2) Penicillin Benzyl Tablets, B.P.
(3) Penicillin Benzyl Capsules
164	Pethidine Hydrochloride with Levallorphan Tartrate	Obstetrical use
165	(1) Phenylbutazone Tablets, B.P..................................................	Rheumatoid arthritis or osteoarthritis not responding to salicylates
(2) Phenylbutazone Capsules ..................................................
Acute attacks of gout
Ankylosing spondylitis
Psoriatic arthritis
Reiter's syndrome
166	(1) Phenylbutazone Suppositories..................................................	For the treatment of the following conditions in persons who cannot tolerate Phenylbutazone Tablets, B.P. and Phenylbutazone Capsules:—
(2) Phenylbutazone Injection..................................................
Acute attacks of gout
Ankylosing spondylitis
Psoriatic arthritis
Reiter's syndrome
Rheumatoid arthritis or osteoarthritis not responding to salicylates
167	Phytomenadione Injection, B.P...................................................	Antidote to anticoagulants
168	Pituitary, Posterior Lobe, Insufflation	Diabetes insipidus
169	Polymyxin B. Sulphate Powder..................................................	With the written authority of the Director-General— Intermittent use by inhalation in fibrocystic disease
170	Polymyxin B. Sulphate Neomycin Sulphate and Hydrocortisone	For the treatment of diseases of the ear
171	Polyoestradiol Phosphate..................................................	Carcinoma of the prostate
172	Prednisolone Sodium Phosphate Retention Enema and Suppository	With the written authority of the Director-General— Ulcerative colitis proven by sigmoidoscopy or radiological report
Proctitis proven by sigmoidoscopy
173	Prednisolone Tablets, B.P..................................................	With the written authority of the Director-General—
Acquired haemolytic anaemia
Acute disseminated encephalomyelitis
Acute exfoliative dermatitis
Acute exophthalmic ophthalmoplegia
Acute heart block complicating myocardial infarction
Acute phase of herpes zoster
Acute rheumatic carditis
Adrenogenital syndrome
Agranulocytosis
Behcet's syndrome
Benign intracranial hypertension
Cerebral oedema
Cerebral tumors
Cranial arteritis
Cushing's syndrome including hyperadrenocorticalism
Dermatomyositis
Encephalitis
Encephalomyelitis
Giant cell thyroiditis proven by biopsy
Guillain-Barré syndrome

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
173	Prednisolone Tablets, B.P.—continued	Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
Hansen's disease
Hepatitis, progressive or continuing proven by biopsy or biochemistry
Hodgkin's disease
Hypoplastic anaemia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Interstitial keratitis due to syphilis or vernal conjunctivitis
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Malignancy treatment in conjunction with radiotherapy or chemotherapy
Malignant exophthalmos
Meningitis
Metastatic breast cancer
Mycosis fungoides
Nephrosis or nephrotic syndrome
Neuromyelitis optica
Nodular nonsuppurative panniculitis (Christian-Weber disease)
Oedema of the spinal cord following trauma or infections
Optic neuritis following removal of tumors of the brain
Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis
Pseudohermaphroditism
Pulmonary cosinophilia
Purpura, Henoch's
Regional ileitis (Crohn's disease)
Reticulum cell sarcoma
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Sneddon and Wilkinson's subcorneal pustular dermatosis
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation for those patients under steroid therapy
Stevens-Johnson syndrome
Still's disease in children under the age of sixteen years
Systemic lupus erythematosus
Sympathetic ophthalmitis
Temporal arteritis
Thrombocytopenic purpura
Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
Typo II nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
174	Prednisolone Methyl Acetate Injection	Intra-articular use

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
175	(1) Prednisolone Acetate Injection	Intra-articular use
(2) Prednisolone Tertiary Butyl Acetate Injection
176	Prednisolone Sodium Phosphate and Neomycin Sulphate	For the treatment of diseases of the car
177	Prednisolone Sodium Succinate................................................	Acute adrenal failure due to medical or surgical crisis
Prophylaxis of adrenal insufficiency during and after major surgery for patients already on steroid therapy
Stevens-Johnson syndrome
178	Prednisone Tablets, B.P................................................	With the written authority of the Director-General—
Acquired haemolytic anaemia
Acute disseminated encephalomyelitis
Acute exfoliative dermatitis
Acute exophthalmic ophthalmoplegia
Acute heart block complicating myocardial infarction
Acute phase of herpes zoster
Acute rheumatic carditis
Adrenogenital syndrome
Agranulocytosis
Behcet's syndrome
Benign intracranial hypertension
Cerebral oedema
Cerebral tumors
Cranial arteritis
Cushing's syndrome including hyperadrenocorticalism
Dermatomyositis
Encephalitis
Encephalomyelitis
Giant cell thyroiditis proven by biopsy
Guillain-Barré syndrome
Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
Hansen's disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin's disease
Hypoplastic anaemia
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Interstitial keratitis due to syphilis or vernal conjunctivitis
Keratoplasty
Leucine sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Malignancy treatment in conjunction with radiotherapy or chemotherapy
Malignant exophthalmos
Meningitis
Metastatic breast cancer
Mycosis fungoides
Nephrosis or nephrotic syndrome
Neuromyelitis optica
Nodular nonsuppurative panniculitis (Christian-Weber disease)
Oedema of the spinal cord following trauma or infections
Optic neuritis following removal of tumors of the brain

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
178	Prednisone Tablets—continued	Panhypopituitarism
Pemphigus
Periarteritis
Progressive transverse myelitis
Pseudohermaphroditism
Pulmonary eosinophilia
Purpura, Henoch's
Regional ileitis (Crohn's disease)
Reticulum cell sarcoma
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Sneddon and Wilkinson's subcorneal pustular dermatosis
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation for those patients under steroid therapy
Stevens-Johnson syndrome
Still's disease in children under the age of sixteen years
Systemic lupus erythematosus
Sympathetic ophthalmitis
Temporal arteritis
Thrombocytopenic purpura
Tropical and non-tropical sprue and forms of malabsorption associated with these diseases
Type II nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
179	Procarbazine Hydrochloride...................................................	Treatment in neoplastic disease
180	Progesterone	Progesterone deficiency proven by hormonal assay of lateral wall smear
181	Propranolol Hydrochloride...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
182	Prosobee ...................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years
183	Protriptyline Hydrochloride ...................................................	Any disease or condition in a pensioner
Any disease or condition in a patient receiving treatment in or at an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Protriptyline Hydrochloride
With the written authority of the Director-General—
The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
184	Pyrazinamide...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
185	(1) Pyridostigmine Injection, B.P.	Myasthenia gravis
(2) Pyridostigmine Tablets, B.P.
186	Pyridoxine Hydrochloride Tablets	Peripheral neuritis due to isoniazid therapy
Radiation sickness
187	Pyrimethamine Tablets...................................................	Treatment of toxoplasmosis

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
188	(1) Quinine Bisulphate Tablets, B.P.	Dystrophia myotonica
Malaria
(2) Quinine Dihydrochloride Tablets	Myotonia atrophica
Myotonia congenita
(3) Quinine Hydrochloride Tablets	Any disease or condition in a pensioner
(4) Quinine Sulphate Tablets, B.P.
189	(1) Riboflavine Tablets...................................................	Any disease or condition in a pensioner
(2) Senna Fruit Extract (standardized)
190	(1) Sodium Aminosalicylate Tablets, B.P.	Tuberculosis
(2) Sodium Aminosalicylate Injection
(3) Sodium Aminosalicylate Cachets
(4) Sodium Aminosalicylate Granules
(5) Sodium Aminosalicylate with Isoniazid, B.P.
191	Sodium Folate...................................................	Macrocytic anaemia
Sprue or the sprue-like syndrome
192	Spiramycin...................................................	Serologically proven active toxoplasmosis
Staphylococcal septicaemia or staphylococcal pneumonia
Any gram positive bacterial infections where these cannot be treated safely and effectively by sulphonamides or penicillins
193	Spironolactone Tablets, B.P...................................................	With the written authority of the Director-General, to supplement other diuretics when these have proved inadequate
Myasthenia Gravis
194	Stanolone ...................................................	Mammary carcinoma
With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
195	Stanozolol ...................................................	With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
196	(1) Stilboestrol Injection...................................................	Carcinoma of the prostate
(2) Stilboestrol Tablets, B.P...................................................	Mammary carcinoma
Any disease or condition in a pensioner
Hereditary Telangiectasis
197	Streptomycin Sulphate Injections	Bacillary dysentery that is resistant to the sulphonamides
Brucellosis
Chancroid
Endocarditis due to Streptococcus faecalis or Streptococcus viridans
Friedlander bacillus infections
Haemophilus influenzae infections
Plague
Pseudomonas pyocyanea infections
Rat-bite fever (Streptobacillus moniliformis)
Salmonella infections
Surgical conditions of the bowel (pre-operative and post-operative)
Surgical conditions of the thoracic organs
Tuberculosis
Tularaemia
Urinary tract infections that are resistant to the sulphonamides

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
198	Sulphasalazine.............................	Ulcerative colitis
199	Sulphomyxin Sodium ..................	Any disease or condition in a patient receiving treatment in or at an approved hospital
200	Sulthiame ...................................	For use where other anticonvulsants have failed
201	(1) Surgical Cement ....................	Ileostomy or colostomy conditions
(2) Surgical Cement Solvent.........	For use with surgical appliances
202	(1) Sustanon ...............................	Castration syndrome (male)
(2) Testosterone Implants, B.P......	Klinefelter Reifenstein Albright syndrome
(3) Testosterone Oenanthate.........	Mammary carcinoma
(4) Testosterone Propionate Injection, B.P.
203	Tetanus Antitoxin, B.P. (Bovine)	Patients who have previously received an injection of equine serum
204	Tetanus Immune Globulin (Human)	With the written authority of the Director-General, where patients are known to be sensitive to equine serum and bovine serum
205	Tetracosactide.............................	Any disease or condition in a patient receiving treatment in or at an approved hospital
206	(1) Tetracycline Capsules, B.P......	A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P., except herpes zoster ophthalmicus
(2) Tetracycline Tablets, B.P........
(3) Tetracycline Injections............
(4) Rolitetracycline......................
(5) Tetracycline Hydrochloride Granules, Paediatric Drops and Syrup
(6) Tetracycline with a buffering agent
207	(1) Tetracycline with a buffering agent and Amphotericin B	A disease or condition specified in this column in relation to Oxytetracycline Hydrochloride with a buffering agent and Nystatin
(2) Tetracycline with a buffering agent and Nystatin
208	(1) Thiambutosine Tablets, B.P.....	Hansen's disease
(2) Thiambutosine Injection..........
209	Thiethylperazine Tablets and Suppositories	Radiation sickness
Nausea resulting from cytotoxic therapy
210	(1) Thioridazine Tablets, B.P........	Any disease or condition in a pensioner
(2) Thioridazine...........................	Any disease or condition in a patient receiving treatment in or at an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits:—
Thioridazine
Thioridazine Tablets, B.P.
With the written authority of the Director-General—
Late-stage malignancy
Radiation sickness
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital

211	Thyrotrophin...............................	Any disease or condition in a patient receiving treatment in or at an approved hospital
212	Tragacanth, Indian (Gum Karaya).	Ileostomy or colostomy conditions
213	Trasylol ......................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
214	Tretamine ...................................	Treatment in neoplastic disease

Fifth Schedule—continued

First Column_Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
215	Triacetylolcandomycin...................................................	Brucellosis
Intestinal amoebiasis
Leptospirosis
Lymphogranuloma venereum
Mycoplasma pneumoniae (Eaton's Agent)
Psittacosis
Rickettsial infections
Staphylococcal septicaemia or staphylococcal pneumonia
Any bacterial infections or spirochaetal infection or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins
Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
216	(1) Trifluoperazine Tablets, B.P...................................................	Any disease or condition in a pensioner
(2) Trifluoperazine Hydrochloride, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Trifluoperazine Hydrochloride, B.P. or Trifluoperazine Tablets B.P.
With the written authority of the Director-General— Late-stage malignancy Radiation sickness
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
217	Triglyde ...................................................	With the written authority of the Director-General— Proven malabsorption
218	Trimetaphan Injection, B.P...................................................	Hypotensive for anaesthesia
219	Vadrine ...................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
220	Vasopressin Nasal Spray ...................................................	Diabetes insipidus
221	Velactin ...................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years
222	(1) Vinblastine Sulphate...................................................	Treatment in neoplastic disease
(2) Vincristine Sulphate...................................................
223	(1) Viomycin Sulphate...................................................	Tuberculosis
(2)Viomycin Sulphate Injection, B.P.
224	Vitamin A with Aneurine Hydrochloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D	Any disease or condition in a pensioner

THE SCHEDULES

FIRST SCHEDULE  Regulation 3.

Amendments of the Second Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. After item 10 insert:—

" 10a Bacitracin Zinc.................................... Bacitracin Zinc with Neomycin Undecenoate ".

2. After item 15 insert:—

" 15a	Buclosamide.......................................	Buclosamide with Salicylic Acid
Buclosamide with Salicylic Acid and Hydrocortisone Acetate B.P.".

3. After item 31 insert:—

" 31a Danthron ............................................ Danthron with Dioctyl Sodium Sulphosuccinate ".

4. After item 41 insert:—

"41a Dioctyl Sodium Sulphosuccinate ......... Dioctyl Sodium Sulphosuccinate with Danthron ".

3. Omit item 61, insert:—

" 61 Glyceryl Guaiacolate .......................... Theophylline with Glyceryl Guaiacolate ".

6. Omit item 64, insert:—

" 64	Hydrocortisone, B.P............................	Hydrocortisone B.P. with Polymyxin B.
Sulphate B.P. and Neomycin Sulphate B.P.".

7. Insert in item 65, after " Hydrocortisone Acetate B.P. with Chloramphenicol B.P." (in the third column), " Hydrocortisone Acetate B.P. with Oxytetracycline Hydrochloride B.P.".

8. Insert in item 83, after " Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin " (in the third column)—

" Polymyxin B. Sulphate B.P. with Hydrocortisone B.P. and Neomycin Sulphate B.P.

Neomycin Sulphate B.P. with Prednisolone Sodium Phosphate B.P.".

9. After item 83, insert:—

" 83a Neomycin Undecenoate ...................... Neomycin Undecenoate with Bacitracin Zinc ".

10. Insert in item 90, after " Oxytetracycline Hydrochloride with a buffering agent and Nystatin B.P." (in the third column), " Oxytetracycline Hydrochloride B.P. with Hydrocortisone Acetate B.P.".

11. Omit from item 92 " XI " (in the second column), insert " XII ".

12. Insert in item 109, after " Polymyxin B. Sulphate B.P. with Propylene Glycol and Acetic Acid " (in the third column), " Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.".

13. Omit item 113, insert:—

" 113 Prednisolone Sodium Phosphate, B.P.... Neomycin Sulphate B.P. with Prednisolone Sodium Phosphate B.P.".

14. Omit item 138, insert:—

" 138	Tetracycline .......................................	Tetracycline with a buffering agent
Tetracycline with a buffering agent and Amphotericin B.
Tetracycline with a buffering agent and Nystatin B.P.".

SECOND SCHEDULE  Regulation 4.

Amendments of the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. Omit from item 17 " Polphydroxy ", insert " Polyhydroxy ".

2. After item 34 insert:—

" 34a. Bacitracin Zinc ".

3. After item 55 insert:—

" 55a. Buclosamide ".

4. After item 92 insert:—

" 92a. Clorexolone ".

5. After item 104 insert:—

" 104a. Danthron ".

6. After item 121 insert:—

" 121a. Dioctyl Sodium Sulphosuccinate ".

7. Omit from item 141 " Discoumarin ", insert " Dicoumarin ".

8. After item 167 insert:—

" 167a. Goat's Milk, Whole (Sterilized) ".

9. Omit item 170.

10. Omit from item 203 " Ehereal ", insert " Ethereal ".

11. After item 210 insert:—

" 210a. Meclastine Hydrogen Fumarate ".

12. After item 238 insert:—

" 238a. Neomycin Undecenoate ".

13. Omit from item 254 " Oxyme ", insert " Oxymel ".

14. Omit from item 287 " Physotiomine ", insert " Physostigmine ".

15. After item 331 insert:—

" 331a. Sorbide Nitrate ".

" 331b. Sorbitol ".

16. Omit from item 353 " Sultiame ", insert " Sulthiame ".

17. After item 385 insert:—

" 383a. Typhoid Vaccine ".

.Printed for the Government of the Commonwealth by W. G. Murray at the Government Printing Office, Canberra